Article

Plasma concentration and acetylator phenotype determine response to oral hydralazine.

Hypertension (Impact Factor: 7.63). 09/1981; 3(5):580-5. DOI: 10.1161/01.HYP.3.5.580
Source: PubMed

ABSTRACT The vasodepressor response to single and multiple oral doses of hydralazine, 1 mg/kg, was studied in hypertensive patients. The concentration of hydralazine in plasma was measured both by a newly developed specific and a nonspecific assay similar to those used in previous studies. Acetylator phenotype was determined following oral sulfamethazine. Plasma hydralazine concentration peaked at 1 hour after administration and was undetectable 2 hours later. Apparent hydralazine was present in plasma in higher concentration and for a longer duration than hydralazine. The peak decreases in blood pressure (BP) were proportional to plasma hydralazine concentration following administration of both single and multiple doses and were substantially maintained for 8 hours. In contrast there was no significant correlation between decreases in BP and apparent hydralazine concentrations. The plasma concentration of hydralazine after a standard oral dose varied by as much as 15-fold among individuals and was lower in rapid than slow acetylator phenotype patients. The BP responses were positively correlated with plasma hydralazine concentrations and inversely correlated with acetylator indices. Low plasma concentrations may account for poor responses of some patients to conventional oral doses of hydralazine. The applicability of acetylator phenotyping for individualization of hydralazine dosage regimens merits further evaluation.

0 Followers
 · 
79 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hydralazine (4) is an antihypertensive agent that displays both mutagenic and epigenetic properties. Here, gel electrophoretic, mass spectroscopic, and chemical kinetics methods were used to provide evidence that medicinally relevant concentrations of 4 rapidly form covalent adducts with abasic sites in double- and single-stranded DNA under physiological conditions. These findings raise the intriguing possibility that the genotoxic properties of this clinically used drug arise via reactions with an endogenous DNA lesion rather than with the canonical structure of DNA.
    Chemical Research in Toxicology 11/2014; DOI:10.1021/tx5003657 · 4.19 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Aim: Hydralazine, a vasodilator used in resistant hypertension (RH) treatment is metabolized by an acetylation reaction mediated by N-acetyltransferase 2, the activity of which depends on NAT2 polymorphisms. Our aim was to evaluate whether different acetylation phenotypes influenced the antihypertensive effect of hydralazine in patients with RH. Patients & methods: DNA samples from 169 RH patients using hydralazine were genotyped by sequencing the NAT2 coding region, and acetylation phenotypes were defined. Results: Sixty-five patients (38.5%) were intermediate, 60 (35.5%) slow and 21 (12.4%) fast acetylators. Twenty-three (13.6%) patients were indeterminate. Upon association analysis, only slow acetylators had significant blood pressure reductions after hydralazine use, with mean 24-h systolic and diastolic blood pressure reductions of 9.2 and 5.5 mmHg. Four patients presented hydralazine adverse effects resulting in drug withdrawal, three of them were slow acetylators. Conclusion: The slow acetylation phenotype, determined by polymorphisms within NAT2, influenced both the antihypertensive and adverse effects of hydralazine in RH. Original submitted 31 May 2013; Revision submitted 7 October 2013.
    Pharmacogenomics 02/2014; 15(2):169-78. DOI:10.2217/pgs.13.202 · 3.43 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: New era has arrived in the biological sciences and pharmaceutical sciences. The concept of personalize medicine used by health care organizations now days. This happens because the vast knowledge of genomics and genetics available now days but still much work is going to persist. Hence the terminologies as Pharmacogenomics or Pharmacogenetics uses very frequently due to great potential in both life sciences as well as pharmaceutical sciences research. In this, physicians or doctors would test each patient before treatment to prevent from lack of efficacy and avoid adverse drug reactions with the help of genome sequence and bioinformatics tools to understand decipher DNA and treat according to that. N-acetyltransferase is one of the most important drug metabolism involved in clinical drug trails which contains slow and fast acetylators. Acetylator is a genetic trait found in normal individuals that can help determine the effects and visible result of medical treatment of various doses of prescribed drugs. Particularly individual has either Fast Acetylator or Slow Acetylator. Fast Acetylator is having dominating nature on the Slow Acetylator. This paper give overview of Acetylator Phenotype and researches components that strike the utility of this information in medical or clinical practice to avoid problems occurring due to incorrect metabolism of the routinely prescribed drugs. INTRODUCTION Today science has gone beyond the orthodox concept treating disease or disorder in human being. In next 10 to 20 years the term known as personalized medicine become more popular than traditional therapeutic medicine practice. This development is happens due to more knowledge of genetic components of individuals combination with Pharmaceutical science. Hence, awareness of important characteristic of individual increase because of genomic science. Hence research of drugs and treatment going to more focus on single individual in future which is not far away. Pharmacogenomics and Pharmacogenetics As per the normal designation of the Pharmacogenomics explain as it is science to study knowledge of genomics and proteomics to recognize the new drug targets and mechanism of their action. Whereas the Pharmacogenetics explains as it is science of to study the inter-individual specific genetic variation correlated to drug response. [1] When these two ways comes together then it help to pharmaceutical and health care related sectors by facilitated by drug development and personalized medicine for more drug safety and prevents its adverse effects. But current scenario, the very few applications have shown successful outputs in clinical drug practices. [2][3]

Preview

Download
0 Downloads
Available from